Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Madrigal Pharmaceuticals

Explore full profile

The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease

West Conshohocken, United StatesFounded 2011Biotech & Life Sciences
Valuation $11B Market cap · 2026
Revenue $1.52B Latest reported FY

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a biopharmaceutical company dedicated to developing novel therapeutics for nonalcoholic steatohepatitis (NASH), a severe liver disease. The company operates in the healthcare and pharmaceutical market, focusing on patients with moderate to advanced liver fibrosis (stages F2 to F3) and those with compensated cirrhosis. Madrigal's business model revolves around research and development, clinical trials, and the commercialization of its therapies. The company's first therapy has received accelerated approval from the U.S. Food and Drug Administration (FDA) and is currently undergoing Phase 3 clinical trials. Madrigal generates revenue through the sale of its FDA-approved treatments and potentially through partnerships and licensing agreements. The company's target clients include healthcare providers, hospitals, and patients suffering from NASH.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2011
Headquarters
West Conshohocken, United States
Listing
IPO 2016
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Bay City Capital

Series B and later2 investors entered at this stage

  • Hercules Capital
  • Blue Owl Capital

Talent

Book a demo to see the people
Employees mapped 1,175 incl. 4 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 10 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
10 countries with
team presence
🇺🇸 United States88.3%
🇩🇪 Germany4.1%
🇨🇭 Switzerland3.8%
🇫🇷 France0.7%
🇬🇧 United Kingdom0.7%
Top 5 of 10 shown
Web traffic by country
110K monthly visits
across markets
🇺🇸 United States114.9%
🇬🇧 United Kingdom2.1%
🇨🇦 Canada1.8%
🇮🇳 India1.7%
🇯🇵 Japan1.1%
Top 5 markets shown

Patents

Estimated portfolio value
$25M

42 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Madrigal Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Madrigal Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles